Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

In July 2021, Arvinas and Pfizer entered into a global collaboration for the co-development and co-commercialization of vepdegestrant, sharing development costs, commercialization expenses ...

H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...

Investing.com -- Shares of Arvinas Inc (NASDAQ: ARVN) climbed 1.6% while Pfizer Inc (NYSE: PFE) edged up 0.5% following the announcement of a New Drug Application (NDA) submission to the U.S. Food ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

(RTTNews) - Arvinas (ARVN) announced the submission of a New Drug Application to the FDA with its partner Pfizer (PFE), for vepdegestrant for the treatment of patients with ER+/human epidermal ...

Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for ...